Zimbabwe has turned down a major American health deal valued at $367m (272 million pounds) over five years due to Washington's request for confidential biological samples.
This move was revealed following a official document from December was disclosed, which showed President Emmerson Mnangagwa felt the arrangement was "lopsided".
An official spokesman has since clarified that the United States was requesting genetic material for scientific study and commercial purposes but was not willing to guarantee the resulting advantages from any future vaccines.
"We will now turn to the challenging and unfortunate process of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had provided more than $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has appealed for further negotiations to secure a deal suitable to both sides so the country's vital HIV programme can continue.
Wider Context
Zimbabwe's decision comes after a similar case in neighbouring Kenya, where a high court suspended a related deal with the US following concerns were raised about the safety of citizens' health data.
After resuming office last year, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
USAID had overseen aid for the American government, but Trump argued its expenditure was "wasteful" and his government was seeking direct bilateral agreements to boost openness and accountability.
According to statements, 16 African countries have to date signed similar health pacts, representing more than $18.3bn of fresh investment.
Specifics of the Declined Deal
The money for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this collaboration would have delivered immense advantages for Zimbabwean communities, especially the 1.2 million men, women and children currently receiving HIV treatment via US-supported programmes," Tremont added.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to provide its biological resources and data indefinitely, with no equivalent guarantee of access to any medical innovations – such as new medicines or tests – that might result from that shared data," Mangwana explained.
"Put simply, our nation would provide the basic resources for medical research without any certainty that the end products would be accessible to our people should a future pandemic arise."
Sovereignty and Global Health
Mangwana further noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were undermining systems already established through the international health agency.
The spokesperson cited its Pandemic Benefit-Sharing scheme designed to deal with potential pandemics.
"This system is intended to guarantee that when a country contributes its samples, the resulting advantages – including medicines and cures – are shared equitably, not commercialised solely by those with the capability to develop them."
The government's concerns over the US deal "are not meant as opposition to America," Mangwana stressed.
"We are open to further discussions with our US partners on how subsequent collaboration might be structured in a way that honours the sovereignty and dignity of each country."
Health Experts Response
Medical experts said it recognised the official position, but recommended that talks should continue given that much of the country's HIV programmes were funded by foreign aid.
"If technical issues arise, including those involving data governance or implementation frameworks, these can frequently be addressed via technical clarification and mutually agreed protections," it said.
The situation underscores the continuing tensions between accepting crucial foreign assistance and protecting national sovereignty in an increasingly interconnected world.